NCT02670213

A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 8 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is conducted in Asia. Tha aim of this study is to investigate Safety and Effectiveness of NovoThirteen® (rFXIII) during treatment of congenital FXIII deficiency in Japan.

Conditions

• Congenital Bleeding Disorder
• Congenital FXIII Deficiency

Interventions

Type	Name	Description
DRUG	recombinant factor XIII	No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.

Timeline

• Start date: 2016-03-16
• Primary completion: 2024-09-30
• Completion: 2024-09-30
• First posted: 2016-02-01
• Last updated: 2025-08-29

Locations

8 sites across 1 country: Japan